











**NEUROBLASTOMA RESPONSE TO RAS-MAPK INHIBITORS
AND APR-246 (EPRENETAPOPT) CO-TREATMENT IS
DEPENDENT ON SLC7A11 PHOSPHORYLATION.**

SUPPLEMENTARY MATERIAL TO FIGURES 1, 2, 4, 5, 6




Supplement 1: Original photos used for figure 1C




Supplement 2: Original photos used for figure 2A










Supplement 3: Original photos used for figure 4B






Supplement 3: Original photos used for figure 4B and 4C



Supplement 4: Original photos used for figure 5A




Supplement 4: Original photos used for figure 5D



Supplement 5: Original photos used for figure 6A

WB ERK1/ERK2 LLnormal 2021.08.27


"enrichment phosphoProt"



1. SKNSH pmRNA5-ctrl
2. SKNSH pmRNA5-MEKca

WB phosphoERK1/ERK2 LL+ 2021.08.27


"enrichment phosphoProt"



1. SKNSH pmRNA5-ctrl
2. SKNSH pmRNA5-MEKca


WB xCT LL normal 2021.08.27

"enrichment phosphoProt"





1. SKNSH pmRNA5-ctrl
2. SKNSH pmRNA5-MEKca

xCT





1. KCNR - Ctrl
2. KCNR - SCH 10 uM
3. NBL-S - Ctrl
4. NBL-S - SCH 10 uM

Supplement 6: Original photos used for figure 6B



Supplement 7: Original photos used for figure 6C



Supplement 8: Original photos used for figure 6D

